Share Prices & Company Research

Market News

09 Mar 2021 | 15:56

Shield's Feraccru gets registration in Australia

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics said on Tuesday that Australia's Therapeutics Goods Administration (TGA) has registered 'Feraccru' in the country's Register of Therapeutic Goods, to treat iron deficiency with or without anaemia in adults. The AIM-traded firm said Feraccru was already approved in the UK, the European Union, Switzerland and the United States for the treatment of iron deficiency with or without anaemia in adults.

It said Norgine would lead all marketing activities in Australia.

"The Therapeutic Goods Administration is Australia's regulatory authority for medicinal products," the Shield board clarified in its statement.

At 1449 GMT, shares in Shield Therapeutics were down 0.76% at 38.95p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.